서은섭 (성균관대학교 의과대학, 삼성서울병원) | 한빛사논문 > 한빛사

한빛사논문

조회131

서은섭Eun Seop Seo

성균관대학교 의과대학, 삼성서울병원

CV File 42 kb

Cell Rep. Med., May 30 2025, S2666-3791(25)00237-X | https://doi.org/10.1016/j.xcrm.2025.102164 Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype

Eun Seop Seo,^1,2,14 Sabin Park,^3,14 Eun Yoon Cho,^4,14 Jeong Eon Lee,^5,6,14 Hae Hyun Jung,⁷ Jiyeon Hyeon,⁸ Sepil An,⁹Seok Won Kim,⁵ Junghoon Shin,⁸ Jin Seok Ahn,^6,8 Yeon Hee Park,^6,8 Young-Hyuck Im,^6,7,8 Hoon Kim,^9,10,11,* Semin Lee,^3,*Woong-Yang Park,^2,6,12,13,* and Ji-Yeon Kim ^1,6,7,8,15,*

¹Department of Digital Health, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea
²Geninus Inc., Seoul 05836, Republic of Korea
³Department of Biomedical Engineering, College of Information-Bio Convergence Engineering, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea
⁴Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
⁵Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
⁶Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea
⁷Biomedical Research Institute, Samsung Medical Center, Seoul 06351, Republic of Korea
⁸Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
⁹Department of Biopharmaceutical Convergence, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do 16419, Republic of Korea
¹⁰Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do 16419, Republic of Korea
¹¹Epigenome Dynamics Control Research Center, Sungkyunkwan University, Suwon-si, Gyeonggi-do 16419, Republic of Korea
¹²Translational Genomics Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
¹³Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Gyeonggi-do 16419, Republic of Korea
¹⁴These authors contributed equally
¹⁵Lead contact

^*Corresponding authors: correspondence to Hoon Kim, Semin Lee, Woong-Yang Park or Ji-Yeon Kim

Abstract

Residual cancer burden (RCB) is a strong prognostic marker after neoadjuvant chemotherapy (NAC) in breast cancer (BC), yet some BCs defy their predicted outcomes. Using single-cell spatial transcriptomics and genomic profiling, we investigate mechanisms underlying divergent fates of BCs with high RCB across subtypes. In triple-negative BC (TNBC), CXCL9+ macrophage-CD8⁺ T cell interactions via chemokines and interferon-gamma signaling promote favorable outcomes, while SPP1+ macrophage-cancer cell interactions driven by hypoxia signaling correlate with poor prognosis. In non-TNBC, the extent of basal-like cancer cells and their proximity to scarce immune cells are linked to prognosis. Additionally, tumor-intrinsic features-such as homologous recombination deficiency in hormone receptor (HR)-positive cancers and structural variations, including extrachromosomal ERBB2 DNA in human epidermal growth factor receptor 2 (HER2)-positive cancers-predict worse outcomes. This study highlights distinct genomic and microenvironmental strategies governing BC subtype-specific fates after NAC.

논문정보

형식Research article
게재일2025년 05월 (BRIC 등록일 2025-06-10)
연구진국내 연구진
분야 의약학 > 유전 및 유전체의학

댓글 작성 로그인

CV 열람하기

연락처 보기